BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
VANCOUVER, BC, Jan. 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares issued at a deemed price of $0.03 per common share.
- VANCOUVER, BC, Jan. 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares issued at a deemed price of $0.03 per common share.
- None of the debt settled included accrued salaries to officers or directors of the Company, nor does it include payments for Investor Relations Activities.
- The Company relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101.
- All securities issued in connection with the completed Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.